Cargando…

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001

SIMPLE SUMMARY: Prostate-specific membrane antigen (PSMA) is a protein overexpressed in metastatic castration-resistant prostate cancer and a promising target for targeted radionuclide therapy. PSMA-targeted alpha therapy is of growing interest due to the high-emission energy and short range of alph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenberg, Vilde Yuli, Tornes, Anna Julie Kjøl, Nilsen, Hogne Røed, Revheim, Mona-Elisabeth, Bruland, Øyvind Sverre, Larsen, Roy Hartvig, Juzeniene, Asta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179904/ https://www.ncbi.nlm.nih.gov/pubmed/35681766 http://dx.doi.org/10.3390/cancers14112784

Ejemplares similares

Evaluation of the PSMA-Binding Ligand (212)Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
por: Stenberg, Vilde Yuli, et al.
Publicado: (2021)

Targeted alpha therapy with the (224)Ra/(212)Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
por: Tornes, Anna Julie Kjøl, et al.
Publicado: (2022)

Dual targeting with (224)Ra/(212)Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
por: Juzeniene, Asta, et al.
Publicado: (2023)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)

In situ Generated (212)Pb-PSMA Ligand in a (224)Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells
por: Stenberg, Vilde Y., et al.
Publicado: (2020)

Imaging of (212)Pb in mice with a clinical SPECT/CT
por: Kvassheim, Monika, et al.
Publicado: (2023)

An Experimental Generator for Production of High-Purity (212)Pb for Use in Radiopharmaceuticals
por: Li, Ruth Gong, et al.
Publicado: (2023)

Editorial: Targeted alpha particle therapy in oncology
por: Bruland, Øyvind Sverre, et al.
Publicado: (2023)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2010)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
por: Rizzo, Alessio, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

[(212)Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
por: Chapeau, Dylan, et al.
Publicado: (2023)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2014)

Quantitative SPECT/CT imaging of lead-212: a phantom study
por: Kvassheim, Monika, et al.
Publicado: (2022)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
por: Hoshi, Seiji, et al.
Publicado: (2023)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study
por: Kvassheim, Monika, et al.
Publicado: (2022)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2h7fisidqmll3g3i7slb41a3jv